オハイオにおける頭頸部がんの臨床試験
オハイオ内の拠点で、頭頸部がんに関する19件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site#0154, Canton
- Site#0117, Cincinnati
- Site #0151, Cleveland
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06788990The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 10, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07085091A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Tongue Proactive Strengthening Exercise Program Following Partial/Hemi Glossectomy and Reconstruction
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland
被験者募集中
18歳以上 · 全性別 · 2026/08/06更新 · NCT07110142Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT06627270First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- UH Cleveland Medical Center, Cleveland
- Stefanie Spielman Comprehensive Breast Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
被験者募集中第1/2相
18歳〜90歳 · 全性別 · 2026/07/06更新 · NCT06710756Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
- University of Cincinnati Medical Center, Cincinnati
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/01更新 · NCT07213934A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/05/27更新 · NCT03093116A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Canton
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/26更新 · NCT06256588Feasibility Study of CBCT for IGRT in Cancer Patients
- James Outpatient Center, Columbus
- Ohio State University, Brain and Spine Hospital, Columbus
- The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus
- 他1件
被験者募集中
18歳以上 · 全性別 · 2026/03/13更新 · NCT06681233cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
被験者募集中第1/2相
18歳〜80歳 · 全性別 · 2025/12/11更新 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2025/08/15更新 · NCT04429542ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。